Metabolomics for the individualized therapy of androgen deficiency syndrome in male adults

Robin Haring, Kathrin Budde, Henri Wallaschofski

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review


Testosterone is the major circulating androgen in men with a physiological age-related decline in the aging male. Late-onset hypogonadism or Androgen Deficiency Syndrome (ADS) is a syndromic diagnosis including both, persistent low testosterone concentrations together with clinical symptoms including erectile dysfunction, low libido, decreased muscle mass and strength, increased body fat, decreased vitality, and depressed mood. But due to its unspecific symptoms, treatment goals, and monitoring parameters, there are many uncertainties concerning the diagnosis, therapy, and monitoring of ADS to date. The present work intends to introduce the application of metabolomics as a novel and promising tool for the improved diagnosis, therapy, and monitoring of ADS. We will outline the current uncertainties and limitations in the diagnosis and therapy of ADS to subsequently explore the scientific opportunities of metabolomics to account for the specific metabolic requirements and characteristics of the individual patient, better understand the metabolic deviations in testosterone deficiency, and monitor the biochemical changes induced by testosterone replacement therapy. We also discuss the potential of metabolomics to optimize the effectiveness and safety of individualized testosterone replacement therapy, and to thereby significantly reduce the side effects and associated health care costs of ADS treatment.

Original languageEnglish
Title of host publicationGenetics Meets Metabolomics
Subtitle of host publicationfrom Experiment to Systems Biology
EditorsKarsten Suhre
Place of PublicationUnited States
Number of pages17
ISBN (Electronic)9781461416890
ISBN (Print)1461416884, 9781461416883
Publication statusPublished - 2012
Externally publishedYes

Cite this